CN1050715A - 喹啉衍生物及其生产与应用 - Google Patents

喹啉衍生物及其生产与应用 Download PDF

Info

Publication number
CN1050715A
CN1050715A CN90108222A CN90108222A CN1050715A CN 1050715 A CN1050715 A CN 1050715A CN 90108222 A CN90108222 A CN 90108222A CN 90108222 A CN90108222 A CN 90108222A CN 1050715 A CN1050715 A CN 1050715A
Authority
CN
China
Prior art keywords
dihydro
chloro
compound
methyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN90108222A
Other languages
English (en)
Chinese (zh)
Inventor
完治目黑
志池田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN1050715A publication Critical patent/CN1050715A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Holo Graphy (AREA)
  • Detergent Compositions (AREA)
  • Measurement Of Radiation (AREA)
  • Quinoline Compounds (AREA)
CN90108222A 1989-10-06 1990-10-05 喹啉衍生物及其生产与应用 Pending CN1050715A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP262782/1989 1989-10-06
JP26278289 1989-10-06
JP322290/89 1989-12-11
JP32229089 1989-12-11

Publications (1)

Publication Number Publication Date
CN1050715A true CN1050715A (zh) 1991-04-17

Family

ID=26545706

Family Applications (1)

Application Number Title Priority Date Filing Date
CN90108222A Pending CN1050715A (zh) 1989-10-06 1990-10-05 喹啉衍生物及其生产与应用

Country Status (17)

Country Link
US (1) US5223513A (enExample)
EP (1) EP0421456B1 (enExample)
KR (1) KR910007883A (enExample)
CN (1) CN1050715A (enExample)
AT (1) ATE116301T1 (enExample)
AU (1) AU629048B2 (enExample)
CA (1) CA2026890C (enExample)
DE (1) DE69015541T2 (enExample)
FI (1) FI904915A7 (enExample)
HU (1) HUT55364A (enExample)
IE (1) IE903454A1 (enExample)
IL (1) IL95839A (enExample)
NO (1) NO904300L (enExample)
NZ (1) NZ235582A (enExample)
PT (1) PT95515A (enExample)
RU (1) RU2001910C1 (enExample)
TW (1) TW205037B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906735A (zh) * 2011-11-04 2014-07-02 霍夫曼-拉罗奇有限公司 新芳基-喹啉衍生物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
FI934710L (fi) * 1991-04-26 1993-10-25 Pfizer 4-aryl-3-(heteroarylureido)kinolinderivat
JP2668163B2 (ja) * 1992-01-23 1997-10-27 ファイザー インク． コレステロール血症および抗アテローム動脈硬化症薬としての４−アリール−３−（ヘテロアリールウレイド）−１，２−ジヒドロ−２−オキソ−キノリン誘導体
TW241258B (enExample) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
ATE161530T1 (de) * 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
US5565472A (en) * 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
US6133326A (en) 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
US5843957A (en) * 1995-05-19 1998-12-01 Sumitomo Pharmaceuticals Company, Ltd. Naphthyridine derivatives
WO1999009983A1 (en) * 1997-08-28 1999-03-04 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
AU2547399A (en) 1998-02-25 1999-09-15 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for producing the same
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
JP2002531549A (ja) * 1998-12-04 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体
EE200200429A (et) 2000-02-02 2003-12-15 Warner-Lambert Company Kolesteroolestri ja vahaestri sünteesi duaalsed inhibiitorid rasunäärme häirete jaoks
EP1375487B1 (en) * 2001-03-02 2011-08-24 Sumitomo Chemical Company, Limited Process for producing quinoline-3-carboxylic acid compounds
DK1383734T3 (da) * 2001-04-30 2006-05-15 Pfizer Prod Inc Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater
EP1667973B1 (en) * 2003-09-23 2013-12-04 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1216878B (de) * 1963-04-02 1966-05-18 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von coronargefaesserweiternden Derivaten des 7-Hydroxy-2-oxo-1, 2-dihydrochinolins
NO133758C (enExample) * 1970-04-04 1976-06-23 Takeda Chemical Industries Ltd
JPS555502B1 (enExample) * 1971-07-31 1980-02-07
US4530931A (en) * 1983-01-03 1985-07-23 Usv Pharmaceutical Corp. 8-Quinoline carbanilates for the inhibition of lipolysis
EP0166354B1 (en) * 1984-06-26 1992-08-05 Merck & Co. Inc. Benzofused lactam compounds and pharmaceutical compositions containing them
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906735A (zh) * 2011-11-04 2014-07-02 霍夫曼-拉罗奇有限公司 新芳基-喹啉衍生物
CN103906735B (zh) * 2011-11-04 2016-12-07 霍夫曼-拉罗奇有限公司 新芳基-喹啉衍生物

Also Published As

Publication number Publication date
US5223513A (en) 1993-06-29
DE69015541D1 (de) 1995-02-09
AU6370790A (en) 1991-04-11
PT95515A (pt) 1991-08-14
HU906360D0 (en) 1991-04-29
EP0421456A2 (en) 1991-04-10
NO904300L (no) 1991-04-08
ATE116301T1 (de) 1995-01-15
IL95839A (en) 1995-03-15
JPH03223254A (ja) 1991-10-02
FI904915A7 (fi) 1991-04-07
CA2026890C (en) 2001-09-18
EP0421456A3 (en) 1991-05-29
AU629048B2 (en) 1992-09-24
TW205037B (enExample) 1993-05-01
IL95839A0 (en) 1991-06-30
DE69015541T2 (de) 1995-06-01
NO904300D0 (no) 1990-10-03
EP0421456B1 (en) 1994-12-28
CA2026890A1 (en) 1991-04-07
IE903454A1 (en) 1991-04-10
NZ235582A (en) 1992-03-26
FI904915A0 (fi) 1990-10-05
RU2001910C1 (ru) 1993-10-30
KR910007883A (ko) 1991-05-30
HUT55364A (en) 1991-05-28

Similar Documents

Publication Publication Date Title
CN1050715A (zh) 喹啉衍生物及其生产与应用
CN1023404C (zh) 苯并吡喃衍生物的制备方法
CN1031992C (zh) 苯醌衍生物及其药用
CN1027068C (zh) α-取代的4-(喹啉-2-基-甲氧基)苯乙酸和酯的制备方法
CN1020095C (zh) 制备二氯苯胺衍生物的方法
CN1051311C (zh) N－杂芳基－n'－苯脲衍生物及其生产和应用
CN1293192A (zh) 新的苯并噻吩、苯并呋喃和吲哚化合物、其制备方法和含有它们的药物组合物
CN1063869A (zh) 新的含氮双环衍生物，其制备方法，由此得到的新的中间体，其药物用途和含这类物质的药物组合物
CN1159804A (zh) 二氢苯并呋喃
CN1009831B (zh) 杂环氧代-2，3-二氮杂萘基乙酸的制备方法
CN1079219A (zh) 芳基乙酰胺
CN88101588A (zh) 制备1，4-二取代的哌嗪类化合物的方法
CN87104319A (zh) 苯并吡喃衍生物
CN88100153A (zh) 杂芳基3-氧-丙腈衍生物的制备方法
CN1138583A (zh) 9-取代的2-(2-正烷氧基苯基)-嘌呤-6-酮类化合物
CN88102538A (zh) 新的双环化合物、其制备方法以及含这类化合物的药物组合物
CN1034538A (zh) 作为药物有用的双脲衍生物及其制备方法
CN1045972A (zh) 5-取代-1，4-二氢-4-氧代-二氮杂萘-3-羧酸(酯)抗菌药
HK1044534A1 (en) Pyridazin-3-one derivatives and medicines containing the same
CN1006382B (zh) 1，4-苯并噻嗪衍生物的制备方法
CN1993367A (zh) 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
CN1079745A (zh) 新的9-氟-7-氧代-7H-吡啶并[1，2，3-d，e][1，4]苯并嗪-6-羧酸及其酯
CN1052667A (zh) 唑衍生物
CN1112114A (zh) 新的氨基烷基苯并噁唑啉酮和苯并噻唑啉酮，其制备和药物组合物
CN1079744A (zh) 7-氧代-7H-吡啶并[1，2，3，-d，e][1，4]苯并嗪-6-羧酸及其酯

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication